ArticleProceedings of the National Academy of Sciences of the United States of America2006
A rationally designed agonist antibody fragment that functionally mimics thrombopoietin.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 52 citations in OpenAlex.
- Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.BMC veterinary research · 2016Trial
- Chimeric Peptides fromToxins · 2023Article
- Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain.Biotechnology letters · 2023Article
- A strategy for the selection of monovalent antibodies that span protein dimer interfaces.The Journal of biological chemistry · 2019Article
- Development of a sandwich enzyme-linked immunosorbent assay for dTMP-GH fusion protein by rational immunogen selection.AMB Express · 2017Article
- Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.Protein engineering, design & selection : PEDS · 2017Article
- A Novel Peptide Thrombopoietin Mimetic Designing and Optimization Using Computational Approach.Frontiers in bioengineering and biotechnology · 2016Article
- The pharmacology and clinical application of thrombopoietin receptor agonists.International journal of hematology · 2014Review
- Directed evolution of a three-finger neurotoxin by using cDNA display yields antagonists as well as agonists of interleukin-6 receptor signaling.Molecular brain · 2011Article
- High affinity anti-inorganic material antibody generation by integrating graft and evolution technologies: potential of antibodies as biointerface molecules.The Journal of biological chemistry · 2010Article
- Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.Current gastroenterology reports · 2009Article
- New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Biologics : targets & therapy · 2009Article
- Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus.Journal of molecular biology · 2008Article
- New thrombopoietic growth factors.Blood · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By using rational design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created. A peptide with cMpl receptor-binding capability was grafted into different complementarity-determining regions of a fully human Fab scaffold. Functional presentation of the peptide was optimized by using phage display and cell-based panning. Select antibodies and fragments containing two grafted peptides were assayed for their ability to stimulate the cMpl receptor in vitro. Several candidates demonstrated agonist activity in an in vitro cMpl receptor signaling reporter assay, including Fab59, which was estimated to be equipotent to TPO. Fab59 additionally was able to effectively stimulate platelet production in normal mice. These rationally designed mimetic Fabs may provide a therapeutic intervention for thrombocytopenia while avoiding the potential generation of neutralizing antibodies to endogenous TPO. Furthermore, this study demonstrates a method by which short-lived linear peptides with binding activity may be converted to more stable and potent agonists capable of activating cell surface receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.